Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
vrZDRNtRZUUSdZ8f
Listen
